Profusa Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in New York City, New York and currently employs 0 full-time employees. The company went IPO on 2021-12-20. Profusa, Inc. is a commercial stage digital health company. The firm is engaged in the development of a new generation of biointegrated sensors that potentially empower the individual with the ability to monitor their body chemistry. The Company’s technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. Its first clinical offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels in various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery.
PFSA stock price ended at $0.76 on 木曜日, after rising 31.03%
On the latest trading day Apr 02, 2026, the stock price of PFSA rose by 31.03%, climbing from $0.59 to $0.76. During the session, the stock saw a volatility of 57.89%, with prices oscillating between a daily low of $0.57 and a high of $0.90. Notably, trading volume dropped by 11.2M shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 11.3M shares were traded, equating to a market value of approximately $1.0M.
